Clinical Trial Update: THIO Sequenced With Cemiplimab in Advanced NSCLC [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating sequencing of THIO with cemiplimab in advanced non-small cell lung cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Cemiplimab (cemiplimab)
• THIO

Snippet

Sponsor: Maia Biotechnology | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 2 | Status: RECRUITING